<ul class="summary-bullets"><li>The S&amp;P 500 ended Friday 1.1% lower, the Nasdaq 100 fell 2.5%, and the Dow Jones Industrial Average slipped 0.3%.</li><li>CoreWeave recorded its worst week since November last year.</li><li>Tesla introduced the Roadster sports car, a prototype designed in collaboration with SpaceX.&nbsp;&nbsp;&nbsp;</li></ul>U.S. stock indices dropped on Friday, with the Nasdaq 100 recording its worst week in over a year and&nbsp;a half, pulled down by weakness in chip stocks.The S&amp;P 500 ended Friday 1.1% lower, the Nasdaq 100 fell 2.5%, and the Dow Jones Industrial Average slipped 0.3%. The Russell 2000, which tracks small-cap stocks, ended 1.7% lower.S&amp;P 500 futures slipped 0.2%, while Nasdaq-100 futures dropped 0.7%. Dow Jones Industrial Average futures rose just 22 points.&nbsp;&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) dropped 1.2%, and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF</a> (DIA) eased 0.5%. Meanwhile, the Nasdaq-100 tracking&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) fell 2.5% on Friday.&nbsp;&nbsp;Meanwhile, the VanEck Semiconductor ETF (<a href="https://stocktwits.com/symbol/SMH">SMH</a>) and the iShares Semiconductor ETF fell between 3% and 4% amid weakness in Micron Tech (MU), Nvidia (NVDA), Broadcom (AVGO), and most other silicon makers. The broader Vanguard Information Technology ETF (VGT) dropped 3%.The Roundhill Memory ETF (DRAM) fell about 6% on Friday, with most memory chip stocks in the red.&nbsp;Retail sentiment on Stocktwits for QQQ, SPY, and DIA was ‘bearish’ with ‘high’ message volumes.<h2 class="st-heading-2">US Market Drivers</h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Index</td><td>Move</td><td>Close</td></tr><tr><td>Dow Jones Industrial Average</td><td>-0.3%</td><td>52,002.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td></tr><tr><td>S&amp;P 500</td><td>-1.1%</td><td>7,659.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td></tr><tr><td>Nasdaq 100</td><td>-2.5%</td><td>29,187.55&nbsp;&nbsp;</td></tr></tbody></table></figure></div>Anxiety rose among market participants over excessive spending and debt tech firms are taking on to finance AI expansion. Neocloud provider CoreWeave saw its stock tumble almost 12%, extending weekly losses to 25% as its overall debt load ballooned past $51 billion.Michael Rosen, chief investment officer at Angeles, told CNBC that while mounting debt warrants close monitoring, current levels remain far from systemic danger. “Obviously, increased debt issuance is something to observe and continue to watch and be concerned about if it continues to get to levels of excessiveness. But we’re not remotely close to that right now.”&nbsp;Alternatively, Nvidia’s chief Jensen Huang has been publicly advocating for the AI industry by saying the benefits of the technology will soon outweigh the concerns of investors.&nbsp;“All of this is going to pass, and the reason for that is very simple,” Huang told Bloomberg during an event in Berlin. “It’s going to be transformative. It’s going to impact in a very positive way every single industry and every single country. There’s no question it will continue, and we’re at the beginning of that.”&nbsp;<h2 class="st-heading-2">Key Trending Stocks</h2>Apple Inc. (AAPL) is preparing to fight U.K. antitrust regulators over proposed rule changes designed to break the tech giant’s grip on its iPhone tap-to-pay technology.&nbsp;Shares of Michael Saylor-backed Strategy (MSTR) fell on Friday, reversing Thursday’s gains, after MSCI announced it would adopt a new approach to screening companies for its global benchmark indexes that could put the Bitcoin (BTC) treasury firm’s index membership at risk.&nbsp;Uber (UBER) shares were in focus after Guggenheim reiterated its ‘Buy’ rating and $125 price target, calling it a “compelling investment opportunity.”&nbsp;Tesla’s (TSLA) unveiling of its next-generation Roadster on Thursday turned heads as the car<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/Tesla/status/2110913438293647789"> drove</a> off a roller-coaster-like ramp, somersaulting over other Tesla vehicles before using cold-gas thrusters to land, but analysts saw it as a precursor to its merger with SpaceX (SPCX).&nbsp;Shares of ExxonMobil (XOM) advanced modestly on Friday after the company said that higher refining margins could add about $4.5 billion to third-quarter results compared with the prior quarter.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on September 14, 2026. (Photo by Michael M. Santiago/Getty Images)

Nasdaq 100 Records Worst Week In 18 Months As Investors Steer Clear Of Chipmakers — AAPL, MSTR, UBER, SOXX In Focus

The Philadelphia Semiconductor Index fell for an eighth straight day, the longest slide since 2008.

Equity

Apple Inc

SPDR Dow Jones Industrial Average ETF

Roundhill ETF Trust - Roundhill Memory ETF

NVIDIA Corp

Invesco QQQ Trust Series 1

VanEck Semiconductor ETF

Philadelphia Semiconductor Index

Direxion Daily Semiconductor Bull 3X Shares

iShares Semiconductor ETF

SpaceX

SPDR S&P 500 ETF Trust

Tesla Inc

Exxon Mobil Corp

<ul class="summary-bullets"><li>Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.</li><li>Novartis has faced multiple clinical setbacks over the past several weeks, including trial failures and development discontinuations.</li><li>According to data from Koyfin, 8 of the 23 analysts rate the stock a ‘buy’ or ‘strong buy,’ while 13 rate it a ‘hold’ and only two rate it ‘sell.’</li></ul> Shares of Novartis (NVS) closed little changed on Friday after the company decided to discontinue its mid-stage trial of iptacopan in lupus nephritis.According to a federal clinical trials registry update, the company has concluded the study over ‘strategic considerations.’ It is unclear if the discontinuation was spurred by efficacy or safety concerns.The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment. The company decided to conclude the study after completing the first part, as per the database.Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.<h2 class="st-heading-2">Latest Pipeline Setback For Novartis</h2>Novartis has faced multiple clinical setbacks over the past several weeks. Last month, the company said that its late-stage trial of Pelacarsen, being developed as a treatment to lower elevated lipoprotein(a) or Lp(a) and reduce the risk of major cardiovascular events, missed its primary goal. The company also said that its late-stage trial of del-desiran in myotonic dystrophy type 1 (DM1) missed its primary endpoint.Besides the late-stage drug failures, the company also discontinued development of VHB937 in mid-September after a mid-stage study missed primary and secondary goals. &nbsp;Prior to that, in August, Novartis paused multiple autoimmune and neurology trials after three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) in patients taking its experimental therapy Rap-cel. &nbsp;According to data from Koyfin, 8 of the 23 analysts rate the stock a ‘buy’ or ‘strong buy,’ while 13 rate it a ‘hold’ and only two rate it ‘sell.’<h2 class="st-heading-2">How Did NVS Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVS" data-symbol-id="NVS" href="https://stocktwits.com/symbol/NVS" target="_blank">NVS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.NVS stock has gained 9% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/asnd-shares-shrug-off-positive-european-opinion-for-fda-approved-achondroplasia-drug/cZxKWRBRBtT">ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback 

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. 

Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. 


Dimensional ETF Trust - Dimensional International Core Equity Market ETF

Dimensional International Value ETF

Novartis AG

<ul class="summary-bullets"><li>Final European Commission authorization is still pending, with a decision expected in the fourth quarter of 2026 and a potential first launch in Germany in the first quarter of 2027.</li><li>Ascendis has three approved commercial products.</li><li>TransCon CNP, marketed as YUVIWEL in the U.S., received FDA approval in February 2026.</li></ul>Ascendis Pharma (ASND) said on Friday that it has received a positive European regulatory opinion for its once-weekly treatment for children with achondroplasia.Shares of the company closed down 0.6%, as investors likely viewed the positive opinion as expected, provided it is already approved in the U.S. TransCon CNP, marketed as YUVIWEL in the U.S., received FDA approval in February 2026 to increase linear growth in children two years and older with open growth plates.<h2 class="st-heading-2">CHMP Opinion On Ascendis Drug</h2>Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia for children two years of age and older whose epiphyses, or the expanded end of a long bone, are not closed. The opinion followed review of data from three randomized, double-blind, placebo-controlled trials plus up to three years of open-label extension results, including the pivotal ApproaCH trial. Final European Commission authorization is still pending, with a decision expected in the fourth quarter of 2026 and a potential first launch in Germany in the first quarter of 2027.Chief Executive Officer Jan Mikkelsen said the positive opinion reflects the unique profile of TransCon CNP and that the therapy remains a foundational product in the company’s growth disorder portfolio supporting its longer-term objectives.Ascendis has three approved commercial products, including TransCon CNP. In the second quarter, or its first quarter of commercial sales, the drug recorded €7.6–8 million in revenue, accounting for a small portion of the company’s overall product revenue of €315 million. YORVIPATH accounts for a lion’s share of the company’s overall sales.<h2 class="st-heading-2">How Did ASND Retail Traders React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/ASND">ASND stock</a>&nbsp;stayed within bearish territory over the past 24 hours, while message volume stayed within normal levels.ASND stock has gained 6% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omeros-shares-slide-after-chmp-upholds-negative-opinion-on-drug-analyst-sees-buying-opportunity-at-16/cZxKQ9ERBtG">Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ascendis Pharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.

Ascendis Pharma

iShares Biotechnology ETF

T Rowe Price Capital Appreciation Equity ETF

<ul class="summary-bullets"><li>Bearish investors accumulated roughly $32 billion in paper profits over seven days as the Philadelphia Semiconductor Index dropped over 12% during an eight-session slump.&nbsp;</li><li>Broad market indexes felt the ripple effect, with the S&amp;P 500 on track for its worst weekly decline since June and the Nasdaq 100 sliding 5%.&nbsp;</li><li>Short sellers betting against AI cloud provider CoreWeave Inc. netted more than $1 billion in mark-to-market profits following distressed debt signals and rising default risks.&nbsp;</li></ul>Short sellers have bagged a multi-billion-dollar payday amid a retreat in semiconductor stocks driven by CoreWeave’s debt concerns.&nbsp;Short sellers recorded $32 billion in gross paper profits over a seven-day span as the Philadelphia Semiconductor Index plummeted more than 12%, S3 data showed, as quoted by Bloomberg.&nbsp;The sector benchmark, widely known as the <a class="mention" data-mention="$SOX" data-symbol-id="SOX" href="https://stocktwits.com/symbol/SOX" target="_blank">SOX</a>, extended its slump to eight consecutive trading days on Friday, putting it on pace to mirror its longest losing streak since 2006.<h2 class="st-heading-2">Market Anxiety Around AI Spending Persist&nbsp;</h2>The recent decline reflects growing market anxiety about elevated interest rates, lofty tech valuations, and the massive AI capital expenditures.The selloff in chips has spilled over into broader equity benchmarks, setting the S&amp;P 500 up for a 1.7% weekly decline, its steepest since June, while the tech-heavy Nasdaq 100 dropped 5% in the week ending October 16.Out of the 30 companies comprising the SOX index, 20 have lost over 10% of their value since the downturn began. Coherent Corp.(COHR) led the losses with a dive of nearly 30%."The run up in chips was very aggressive so invariably there was going to be some consolidation or pull back," Dec Mullarkey of SLC Management told Bloomberg.<h2 class="st-heading-2">CoreWeave Shorts Yield Massive Returns</h2>Short sellers targeting CoreWeave Inc. (CRWV), an AI-focused cloud computing firm, logged over $1 billion in gains as the company's equity dropped more than 20% over the week.CoreWeave's debt instruments slipped into distressed territory, with credit-default swaps indicating a greater than 50% likelihood of default over the next five years.S3 data noted that a portion of the short interest in CoreWeave stems from convertible bond arbitrage strategies rather than purely directional bearish bets."CoreWeave specifically is going to need a new story," Joe Tigay, portfolio manager of the Rational Equity Armor Fund told Bloomberg. "It's going to need time to digest this new reality."The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) dropped 1.2%, and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF</a> (DIA) eased 0.5%. Meanwhile, the Nasdaq-100 tracking&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) fell 2.5% on Friday.&nbsp;&nbsp;&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Short Sellers Have Earned $32B Over The Past Week Amid Chipmaker Selloff: Report

Short sellers have bagged a multi-billion-dollar payday amid a retreat in semiconductor stocks driven by CoreWeave’s debt concerns.

Short Sellers Have Earned $32B Over The Past Week Amid Chipmaker Selloff

The recent drop in semiconductor stocks led by CoreWeave has generated an estimated $32 billion in paper gains for bearish investors in just seven days.

Coherent Corp

CoreWeave Inc

<ul class="summary-bullets"><li>Bernstein’s updated stock price is about 17% lower than SKYD’s Thursday closing price.&nbsp;</li><li>Bernstein expects volatility to persist as investors assess cash flow uncertainties.&nbsp;</li><li>Nine out of 22 analysts rate the stock ‘sell’, nine say ‘hold,’ and four say ‘buy,’ with an average 12-month price target of $8.87 a share, as per Koyfin data.</li></ul>Skydance (SKYD) share price fell about 5.3% on Friday and was on track to lose 25% so far this week, putting it on pace to be the S&amp;P 500's top weekly laggard after Bernstein SocGen Group lowered its price target on the stock due to cash flow and balance sheet uncertainty.Bernstein SocGen Group lowered its price target on Skydance Corporation (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/equities/viacom-cl-b">SKYD</a>) to $6.00 from $12.00 while maintaining an Underperform rating.<h2 class="st-heading-2"><a class="mention" data-mention="$SKYD" data-symbol-id="SKYD" href="https://stocktwits.com/symbol/SKYD" target="_blank">SKYD Stock</a>: Bernstein View&nbsp;</h2>Bernstein anticipates continued volatility as market participants grapple with questions about balance sheet health, leverage levels, and cash flow outlook.“We maintain our pre-deal Underperform rating for SKYD and lower our price target to $6. We expect volatility to persist as investors grapple with uncertainties around synergies, FCF generation, leverage, and the balance sheet," Bernstein SocGen analyst Laurent Yoon stated."At this stage, none of those factors appear particularly encouraging. While the long-term opportunity is meaningful, this remains very much a show me story with considerable execution risk in the years ahead,” Yoon added. "The market has reflected these concerns, with the stock currently trading at $7.26, down over 20% in the past week alone and down 56% over the past year.&nbsp;<h2 class="st-heading-2">Skydance’s Valuation And Debt Concern</h2><a href="https://stocktwits.com/news-articles/markets/equity/skyd-stock-slips-premarket-morningstar-says-skydance-s-streaming-ambitions-face-a-12-valuation-and-heavy-debt-burden/cZxWqOTRBAN">Skydance's estimated fair value</a> has fallen after investors began trading separately issued warrants tied to its acquisition of Warner Bros. Discovery. Morningstar analyst Matthew Dolgin slashed his valuation to $12 per share from $15 on Thursday.Class B shareholders who owned shares on Oct. 13 received one warrant for each full share. Starting Oct. 14, investors could trade these warrants separately from Skydance stock.&nbsp; Morningstar's revised valuation excludes the value of those rights, which previously accompanied the shares.The Warner Bros. Discovery transaction also leaves Skydance with huge financial obligations. Skydance CEO David Ellison and his family&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/skyd-stock-in-focus-ellison-family-bets-17-b-on-skydance-what-s-next-for-the-new-media-giant/cZDU9SRRBNG">reportedly</a> invested about $17 billion to help fund the $110 billion deal. They bought an estimated 1.4 billion shares at $12 each, adding to their earlier investment in Paramount.The analyst expects Skydance to pursue major savings by combining operations, but he remains skeptical that the company can hit its $6 billion annual cost-reduction target.&nbsp;<h2 class="st-heading-2">SKYD Stock: Retail View&nbsp;</h2>On Stocktwits, retail sentiment on the stock was ‘extremely bullish’ with ‘high’ message volumes.&nbsp;A user was concerned by the firm’s debt level.<stembedurl>https://stocktwits.com/DragonOfBosnia/message/666718479</stembedurl>SKYD stock has declined 49% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Skydance (Sky Dance) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Skydance On Track To Be The Week's Worst-Performing S&P 500 Stock: Bernstein SocGen Halves Price Target On Cash Flow Uncertainty

Bernstein SocGen Group lowered its price target on Skydance Corporation to $6 from $12.

Skydance Corp. - Ordinary Shares - Class B

<ul class="summary-bullets"><li>H.C. Wainwright views the weakness following the morning’s negative Committee for Medicinal Products for Human Use opinion as overdone and sees a buying opportunity ahead of the next quarterly update.</li><li>Today’s decision, H.C. Wainwright said, does not change its forecasts, valuation, or investment thesis, while reiterating a Buy rating with a $33 price target.</li><li>The company now plans to license commercialization rights to a third party in the European Union (EU) if EU marketing authorization is granted.</li></ul>Shares of Omeros Corp (OMER) slumped 15% on Friday after a European Medicines Agency committee upheld a negative opinion on its drug for a serious post-transplant condition, though H.C. Wainwright dismissed the selloff as overdone.The stock is now on track for its steepest one-day decline since late June.<h2 class="st-heading-2">What Did The Analyst Say?</h2>H.C. Wainwright views the weakness following the morning’s negative Committee for Medicinal Products for Human Use opinion as overdone and sees a buying opportunity ahead of the next quarterly update. The firm said it had already removed Europe entirely from its model when it lowered its price target to $33 in June after the committee's initial negative opinion.Today’s decision, H.C. Wainwright said, does not change its forecasts, valuation, or investment thesis, while reiterating a Buy rating with a $33 price target. The price target still implies a potential upside of about 100% from the stock’s current trading levels around $16.<h2 class="st-heading-2">Second European Rejection For Yartemlea</h2>The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. This followed a re-examination of the committee’s original negative decision from June.An eight-member ad hoc expert group recommended that outside experts examine individual patient data to better understand factors linked to treatment response and survival, the company said. Omeros said it had submitted substantial patient-level data in August, but the CHMP did not share those records with the expert panel.<h2 class="st-heading-2">US Approval Stands In Contrast</h2>Narsoplimab targets a rare and potentially fatal complication called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), which damages small blood vessels after stem cell transplants. The U.S. Food and Drug Administration approved it in December 2025 as the first and only treatment for the condition in patients aged two and older. No approved therapy exists for TA-TMA in Europe.“We are deeply disappointed in the re-examination process and outcome,” said Omeros CEO Gregory A. Demopulos.The company also said that it will terminate the compassionate use program for the drug in the EU and focus on its U.S. market. Current patients will receive enough supply to finish treatment, Omeros added.The company now plans to license commercialization rights to a third party in the European Union (EU) if EU marketing authorization is granted.<h2 class="st-heading-2">How Did OMER Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$OMER" data-symbol-id="OMER" href="https://stocktwits.com/symbol/OMER" target="_blank">OMER stock</a> stayed within the bearish territory over the past 24 hours, while message volume rose from normal to high levels.A Stocktwits user noted that the company has a partnership in place with Danish drugmaker Novo Nordisk for another drug called zaltenibart, which will eventually bring in milestone payments.<stembedurl>https://stocktwits.com/resq1/message/666714149</stembedurl>Another user said they weren't expecting “this big of a downward move.”<stembedurl>https://stocktwits.com/Chronite/message/666685540</stembedurl>OMER stock has fallen 6% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/xom-stock-climbs-on-4-5-b-refining-lift-estimate-goldman-sees-q3-eps-exceeding-wall-street-expectations/cZxKaeZRBsU">XOM Stock Climbs On $4.5B Refining Lift Estimate; Goldman Sees Q3 EPS Exceeding Wall Street Expectations</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. 

iShares Russell 2000 ETF

Omeros Corp

Vanguard Total Stock Market ETF

<ul class="summary-bullets"><li>The SOX index shed more than 12% over the previous seven sessions, wiping out roughly $2 trillion in market value.</li><li>More than half of SOX constituents were down at least 10% from their respective highs.</li><li>The current drawdown marks the index’s fifth correction of at least 10% this year.</li></ul>Semiconductor stocks were enduring one of their sharpest sell-offs in years on Friday, with the Philadelphia Semiconductor Index (SOX) on track to end eight consecutive trading sessions in the red.&nbsp;The index had fallen more than 13% over the previous seven sessions, wiping out roughly $2 trillion in market value, according to TradingView data. A further decline on Friday would extend the streak to eight sessions, with the index&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cantor-cuts-ai-infrastructure-stock-price-targets-terawulf-hut-8/cZxKE8URBsn">under pressure</a> from concerns over AI spending, rising interest-rate expectations and intensifying competition in the memory-chip market.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/SOX_2026_10_16_14_04_11_4f2eb7322c.png" alt="SOX_2026-10-16_14-04-11.png" width="2628" height="1588"><figcaption>SOX price performance over the past seven days and on October 16 as of 12:30 p.m. ET | Source: TradingView</figcaption></figure>The losing streak matches the index’s longest since the 2008 financial crisis, flipping the script on the sector, which has been one of the biggest beneficiaries of the artificial intelligence (AI) boom.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/SOX_2026_10_16_12_52_20_c1e255912b.png" alt="SOX_2026-10-16_12-52-20.png" width="1794" height="974"><figcaption>SOX price performance in 2008 when it fell for eight consecutive sessions. | Source: TradingView</figcaption></figure>The index also logged its fifth correction of at least 10% this year. More than half of the stocks listed within the index are down at least 10% from their respective highs.<figure class="image"><img src="https://news.stocktwits-cdn.com/SOX_corrections_on_chart_1_93e1bf6af8.png" alt="SOX_corrections_on_chart (1).png" width="1794" height="974"><figcaption>SOX corrections of 10% year-to-date on October 16 as of 12:30 p.m. ET. | Source: TradingView</figcaption></figure>The&nbsp;<a href="https://stocktwits.com/symbol/SOXQ">Invesco PHLX Semiconductor ETF</a> (SOXQ), which tracks SOX, slipped 2.6% in midday trade. On Stocktwits, retail sentiment around SOXQ slipped to ‘bearish’ from ‘neutral’ territory over the past day.<h2 class="st-heading-2">Chip Stocks Face Widespread Losses</h2>Nvidia (<a href="https://stocktwits.com/symbol/NVDA">NVDA</a>), the largest constituent of the Philadelphia Semiconductor Index, has fallen more than 11% from its 52-week high. The pullback has been steeper among several semiconductor equipment makers, including Applied Materials (AMAT) and KLA Corp. (KLAC), pointing to weakness extending beyond chip designers.Memory stocks have also come under pressure, with Micron Technology (MU) down sharply from its high.&nbsp;Semiconductor stocks have lost about $2 trillion in market value in the current sell-off. Measured from each stock’s own 52-week high, the losses add up to roughly $4 trillion.<img src="https://news.stocktwits-cdn.com/d_S_Qu4_the_10_biggest_sox_stocks_and_how_far_they_ve_fallen_76c3b4ff4c.png" alt="dSQu4-the-10-biggest-sox-stocks-and-how-far-they-ve-fallen-.png">The pullback follows a powerful rally earlier this year driven by expectations of sustained AI-related demand. Despite the recent losses, the index remained up nearly 60% this year so far.<h2 class="st-heading-2">Strategists Warn Against Turning Too Bearish</h2>The sell-off has raised questions about whether investors are reassessing the AI trade or simply locking in gains after a strong rally. Brett Pachuba of SpotGamma&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stock-sell-off-could-catch-bearish-investors-off-guard-in-right-tail-risk/cZxKRsrRBsX">cautioned</a> on Friday that investors could miss a sharp rebound if positive news from major technology companies reignites demand for AI stocks.“I still believe that there remains a real right tail risk in this market where if you are underinvested to the upside, and we get positive news out of say a Meta or a Google… then there could be a real strong upside chase into a part of the year that has really strong seasonals,” Pachuba told CNBC. “So I do think investors really have to watch out as they kind of step into this bearish mode here.”Dave Maza, CEO of Roundhill Investments, said investor sentiment toward memory stocks had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dram-etf-record-weekly-losing-streak-roundhill-ceo-investor-sentiment-has-turned/cZxhcl7RBrQ">turned negative</a>, citing concerns about Chinese competition, comments from Broadcom CEO Hock Tan and a challenging macroeconomic backdrop.&nbsp;Maza maintained that demand for memory chips remains strong, with supply sold out through 2027 and customer demand extending into 2028.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stock-sell-off-could-catch-bearish-investors-off-guard-in-right-tail-risk/cZxKRsrRBsX">AI Stock Sell-Off Could Catch Bearish Investors Off Guard In ‘Right Tail Risk’, But Wall Street Feels Broader Market Signals Are Holding Up</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on October 14, 2026 in New York City after CPI for September showed a rise of 0.6% with its year over year gain coming in at 3.7%. (Photo by Michael M. Santiago/Getty Images)

Chip Stocks’ On Track For 8-Day Slide Erasing $2 Trillion, Matches Worst Streak Since Financial Crisis

Semiconductor stocks were enduring one of their sharpest sell-offs in years on Friday, with the Philadelphia Semiconductor Index (SOX) on track to end eight consecutive trading sessions in the red.

$2 Trillion Lost In Eight Sessions: Semiconductor Stocks Face Historic Rout

The Philadelphia Semiconductor Index was on track for an eighth consecutive daily decline on Friday.


Applied Materials Inc.

Broadcom Inc

Micron Technology Inc

Invesco PHLX Semiconductor ETF

<ul class="summary-bullets"><li>The company said it saw no volume losses tied to Middle East events in the third quarter.</li><li>Goldman Sachs analyst Neil Mehta said the filing implied Q3 earnings per share near $4.10.</li><li>Exxon is slated to announce full results for the quarter on Oct. 30.</li></ul> Shares of ExxonMobil (XOM) advanced modestly on Friday after the company said that higher refining margins could add about $4.5 billion to third-quarter results compared with the prior quarter.As of the time of writing, XOM traded 2% higher at about $178.04.<h2 class="st-heading-2">What Did Exxon Say?</h2>In the second quarter, Exxon’s adjusted earnings stood at $14.7 billion. Compared with the prior quarter, estimated market effects in the third quarter include a $1.3 billion hit from lower oil and liquids prices in the production business, a $0.3 billion gain from higher natural gas prices, and a net $4.4 billion boost from better product margins, the company said in a filing with the Securities and Exchange Commission.Margin improvement is expected to come mainly from a $4.5 billion rise in the refining and fuels business, partly offset by a $0.6 billion decline in chemicals and a $0.5 billion gain in specialty products.Other planned and seasonal factors included a $0.2 billion benefit from less scheduled maintenance, a $0.6 billion drag from outside disruptions to operations, a $0.3 billion lift from having more days in the third quarter, and a $0.9 billion reduction in the production business from items such as contract entitlements and sales timing. The company said it saw no volume losses tied to Middle East events in the quarter.Goldman Sachs analyst Neil Mehta said the filing implied earnings per share near $4.10. That sits above FactSet consensus of roughly $3.87, but below the firm’s own $4.33 estimate, it said. Goldman holds a ‘Neutral’ rating and a $169 price target on the shares. Exxon is slated to announce full results for the quarter on Oct. 30.<h2 class="st-heading-2">How Did XOM Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$XOM" data-symbol-id="XOM" href="https://stocktwits.com/symbol/XOM" target="_blank">XOM stock</a> stayed within the bearish territory over the past 24 hours, while message volume stayed at normal levels.A Stocktwits user cheered the stock approaching its 52-week high of $178.69.<stembedurl>https://stocktwits.com/mwhite523/message/666710086</stembedurl>XOM stock has gained 48% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/jim-cramer-says-starbucks-can-rise-on-its-own-apple-s-audience-is-worth-paying-for-and-intel-investors-need-patience/cZx0kBeRBrn">Jim Cramer Says Starbucks Can Rise On Its Own, Apple’s Audience Is Worth Paying For, And Intel Investors Need Patience</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Gas prices at a Chicago station have surged sharply, with regular unleaded reaching $5.79 per gallon and Supreme+ hitting $6.79.on April 30, 2026. (Photo by Jacek Boczarski/Anadolu via Getty Images)

XOM Stock Climbs On $4.5B Refining Lift Estimate; Goldman Sees Q3 EPS Exceeding Wall Street Expectations

Margin improvement is expected to come mainly from a $4.5 billion rise in the refining and fuels business, the company said in a filing.

Vanguard S&P 500 ETF

<ul class="summary-bullets"><li>Ryzumvi contains phentolamine ophthalmic solution 0.75%, which reduces pupil size to improve near vision without affecting longer-distance vision.</li><li>The approval was supported by two Phase 3 trials.</li><li>Opus is studying Ryzumvi for vision problems in dim lighting after laser eye surgery.</li></ul>Opus Genetics (IRD) was in the spotlight on Friday, after the U.S. Food and Drug Administration approved its eye drop for treating presbyopia, an age-related condition that makes it difficult to focus on nearby objects.The approval expands the use of an already commercialized therapy and triggers a milestone payment from commercial partner Viatris (VTRS).At the time of writing, <a class="mention" data-mention="$IRD" data-symbol-id="IRD" href="https://stocktwits.com/symbol/IRD" target="_blank">IRD shares</a> were trading 3.4% lower, while <a href="https://stocktwits.com/symbol/VTRS">VTRS stock</a> gained about 1%.<h2 class="st-heading-2">Approval Based On Two Phase 3 Trials</h2>Opus’ Ryzumvi contains phentolamine ophthalmic solution 0.75%, which reduces pupil size to improve near vision without affecting longer-distance vision. The approval was supported by two Phase 3 trials, VEGA-2 and VEGA-3, which met their primary and key secondary goals without serious treatment-related side effects.Notably, 27.2% of patients receiving the eye drop saw an improvement of at least 15 letters (three lines) on an eye chart, compared with 11.5% receiving a placebo.The drug previously received <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-25-011410/ef20039022_10k.htm">FDA approval</a> in September 2023 to reverse pupil dilation caused by medications used during eye examinations. Viatris launched it commercially in April 2024.The companies’ licensing <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm">agreement</a> dates back to November 2022, when Ocuphire Pharma, which acquired Opus in October 2024, granted Viatris the rights to commercialize the treatment.The agreement included $35 million upfront, up to $130 million in milestone payments, and royalties.<h2 class="st-heading-2">IRD Finances To Support Operations Into 2029</h2>Opus is developing gene therapies for inherited retinal diseases, including OPGx-BEST1 for Best disease and OPGx-LCA5 for severe inherited vision loss. The company is also studying Ryzumvi for vision problems in dim lighting following laser eye surgery.Opus reported $88.8 million in cash and cash equivalents as of June 30, and has a financing option of up to $120 million under an agreement with Oberland Capital. The company expects its cash position to support operations into 2029.<h2 class="st-heading-2">IRD, VTRS See Strong Gains In 2026</h2>Retail sentiment surrounding both IRD on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes. Meanwhile, sentiment for VTRS remained ‘neutral’.IRD shares have seen strong buying interest so far this year, surging 84%. Meanwhile, VTRS stock has gained about 48%.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/mi-medx-sanara-merger-faces-fresh-regulatory-obstacle-smti-stock-falls-below-this-key-support-level-for-the-first-time-in-4-months/cZxKJ0GRBsM">MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.

Opus Genetics Inc.

Viatris Inc

SPDR S&P Biotech ETF

<ul class="summary-bullets"><li>JPMorgan's Misra said AI-driven competition for capital and economic resilience helped push bond yields higher.</li><li>She viewed the market's pricing-in of three additional Fed rate hikes as overdone, while considering one or two reasonable.</li><li>Misra warned that sufficiently high real interest rates could cause something to break, pointing to leverage across financial markets.</li></ul>Artificial intelligence (AI) investment has helped push bond yields higher, but JPMorgan Asset Management's Priya Misra sees high-quality fixed income as a potential hedge if momentum in the AI trade fades.Speaking to Bloomberg Television on Friday, the Core Plus Bond ETF portfolio manager attributed the rise in rates partly to economic resilience and AI-driven competition for capital.&nbsp;She noted that much of the increase in longer-term yields reflected higher real interest rates rather than inflation expectations. Misra also argued that much of the competition for capital and the higher cost of borrowing were already reflected in bond prices.The benchmark 10-year U.S. Treasury yield stood at around 5.09% on Friday morning, down from approximately 5.24% at the end of the previous week, amid a rally in government bonds as AI-related stocks came under pressure.<h2 class="st-heading-2">Misra Says Markets Have Overpriced Fed Hikes</h2>Misra viewed the bond market's pricing-in of additional Federal Reserve rate hikes as overdone, noting that markets were pricing in three hikes even as the Fed was discussing one or two more, which she considered reasonable.On inflation, she attributed much of the pressure to supply shocks, citing the continuing effects of tariffs and oil prices. Misra also described AI as a structural demand shock, noting that AI demand was not particularly price-sensitive, while its supply-side effects would emerge later.She also cautioned that sufficiently high real interest rates could cause something to break, pointing to leverage in the financial system and noting that not everyone had unrestricted access to capital.<h2 class="st-heading-2">Why Misra Still Sees Treasuries As A Safe Haven</h2>Misra maintained that U.S. Treasuries remain a safe-haven asset, citing demand for German government bonds, known as bunds, during the recent sell-off in French government debt.She cited government bond liquidity and governments' ability to raise taxes or reduce spending as factors supporting sovereign debt's safe-haven appeal.Despite a difficult year for bonds, fixed income continued to attract inflows, which Misra partly attributed to the income cushion offered by elevated yields. She viewed high-quality fixed income yielding 6% to 7% as attractive and a potential hedge against weakness in the AI trade.<h2 class="st-heading-2">Treasury-Focused ETFs In Focus</h2>The iShares 20+ Year Treasury Bond ETF (<a href="https://stocktwits.com/symbol/TLT">TLT</a>), which tracks longer-dated U.S. government bonds, and the iShares 7-10 Year Treasury Bond ETF (<a href="https://stocktwits.com/symbol/IEF">IEF</a>), which provides exposure to intermediate-term Treasuries, were both trading marginally lower at the time of writing.On Stocktwits, retail sentiment toward both TLT and IEF remained in 'bullish' territory, accompanied by high message volume.See Also:<a href="https://stocktwits.com/news-articles/markets/equity/imf-chief-says-ai-is-strengthening-global-economy-but-warns-delayed-productivity-gains-could-trigger-shocks/cZxK4QKRBsY">&nbsp;IMF Chief Says AI Is Strengthening Global Economy — But Warns Delayed Productivity Gains Could Trigger Shocks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration shows U.S. dollars in Sao Paulo, Brazil. (Photo by Cris Faga/NurPhoto via Getty Images)

AI Has Driven Bond Yields Higher, Says JPMorgan's Priya Misra — Sees Bonds As Hedge Against AI Trade

Artificial intelligence (AI) investment has helped push bond yields higher, but JPMorgan Asset Management's Priya Misra sees high-quality fixed income as a potential hedge if momentum in the AI trade fades.

Misra says high-quality fixed income offers yields of 6% to 7%, providing investors with an income cushion amid AI-related market volatility.

iShares 7-10 Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Teslas rocket-thruster Roadster demonstration drove intense discussion, but traders largely framed the sharp reversal after an initial pop as a sell the news reaction, questioning the cars practicality and near-term earnings impact. Some see the demo as an impressive technology showcase and speculate it could strengthen a TeslaSpaceX merger case, though no merger has been announced; broader weakness in tech stocks also weighed on shares.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom is caught in a broader semiconductor selloff as investors question the sustainability and financing of AI spending; traders also cite CEO Hock Tans comments about capital constraints and speculative AI investing as adding to the pressure. The community is split between bearish concerns about AI demand and the remarks impact, and bulls who see the decline as a sector-wide pullback and continue to buy on weakness.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp, high-volume selloff with no reported company-specific news has focused discussion on suspected options-expiration pressure near the $10 strike and weakness across biotech stocks. Traders remain focused on the delayed 80th-event update and eventual Phase 3 REGAL data, with bullish dip-buyers viewing the decline as technical while skeptics cite the prolonged quiet period and uncertainty around the trial.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCIs steep selloff amid a broader AI-infrastructure pullback is driving attention, with traders debating whether sector weakness and lingering governance and export-control concerns outweigh the appointment of new CFO Mark Long. Some view the decline as an overdone buying opportunity, while others expect further weakness and question managements credibility.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals steep decline is being discussed amid a broader storage and AI-hardware selloff, with traders citing Toshibas planned HDD capacity expansion and Wells Fargos price-target cut as sources of pressure. Some see the concerns as overblown given AI-driven storage demand and upcoming earnings, while others point to continued selling and weak technical momentum.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

CHPY is drawing attention amid a semiconductor and technology selloff, with traders linking its decline to weakness in chip stocks and concerns about the AI trade. Some investors are buying the dip for the ETFs weekly distributions, while others question payout sustainability and warn that falling semiconductor prices can pressure its share value.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXYs sharp gain has sparked bets on a broader volatility spike, with traders pointing to market weakness and concerns about rates, oil, and geopolitical risks. Views are divided: some expect volatility to climb further, while others see a short-lived pop and cite the ETFs futures exposure and decay as reasons to fade rallies.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is drawing attention after a sharp pullback alongside weakness in AI and growth stocks, with traders debating whether the decline is an overreaction or a sign of further downside. Many are buying or averaging down, while others point to the stocks volatile trading and weakening chart.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

A sharp pullback in biotech stocks, reflected in weakness across the XBI, is driving attention to LABU, whose 3 leverage magnifies sector moves. Traders debate whether the declineoften linked in the discussion to inflation and higher-rate concernsis a buying opportunity or the start of further losses, with some favoring LABD or short trades.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

LABDs gain is drawing attention as traders position for further biotech weakness, citing XBIs decline and concerns that hot inflation data and higher rates could pressure the sector. The bearish view is contested by traders expecting a biotech rebound, with many emphasizing the sharp swings and decay risk of the leveraged inverse ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


News